Experience with EUL During ERVEBO® Submission

Mic McGoldrick
10-Sep-2020
Background

• The second largest outbreak of the Ebola virus disease was occurring at the time the Merck vaccine was being registered and WHO prequalified.

• That led to challenges as a result of the need to supply the investigational vaccine for use in the outbreak while simultaneously qualifying the manufacturing processes and supporting regulatory activities.

• WHO defined an Emergency Use Assessment and Listing Procedure in response to the 2014-2016 Ebola outbreak to define the steps that WHO will follow to establish the:
  • eligibility of products
  • minimum information required
  • assessment to make a product available under a limited time listing status, while further data is being gathered and evaluated

• It is intended for use primarily for public health emergencies of international concern
EUL Experience

• Merck submitted documentation to support WHO Emergency Use Listing (EUL) of ERVEBO® prior to conditional marketing authorization, WHO prequalification and African NRA approval, however, the vaccine was not ultimately listed

• The vaccine was provided to at risk subjects and healthcare providers through other means

• Highlights
  • The EUL process assumes that emergency regulations (EUA) are in place in the country in which the vaccine will be used
  • Those countries which do have EUA are not harmonized
  • It works best for products that are licensed in the country of origin
Lessons Learned

• Emergency regulations did not exist in the countries most impacted by the Ebola virus disease. This and deployment concerns prevented the listing of the vaccine.

• For an unlicensed product, use outside of a clinical protocol requires careful consideration of many aspects, including
  • liability coverage
  • export from the country of origin to the country of use
  • the need to draft package inserts for an investigational product
  • traceability for use and mechanisms to collect safety data

• Enabling early use is its own, discrete, complex, regulated body of work, which requires full time planning and attention (with focus on regulatory pathways)

• The quantity of a developmental vaccine to support clinical trials is much less than needed to curb an outbreak, so vaccine supply should be considered carefully
Conclusion

• Since that time, WHO has updated the EUL guideline based on the issues seen in the ERVEBO® EUL process
  https://www.who.int/diagnostics_laboratory/eual/procedure/en/#:~:text=The%20EUAL%20is%20a%20risk,public%20health%20emergencies%20if%20appropriate.

• WHO is working with global NRAs to align more closely the EUA processes within countries or to have them accept the EUL from WHO to allow Covid-19 vaccine use in their countries.